TENX Tenax Therapeutics Inc.

1.19
+0.04  (+3%)
Previous Close 1.15
Open 1.13
Price To Book 0.73
Market Cap 1743940
Shares 1,465,496
Volume 914,672
Short Ratio
Av. Daily Volume 376,071

NewsSee all news

  1. Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering
  2. Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering
  3. TENX: We Have Liftoff: HELP Site Activated
  4. Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
  5. Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 181235530
  2. 8-K - Current report 181228824
  3. EFFECT - Notice of Effectiveness 181224781
  4. 424B4 - Prospectus [Rule 424(b)(4)] 181224142
  5. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 181219023

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 first site announced November 19, 2018.
Levosimendan
Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)
Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering
  2. Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering
  3. TENX: We Have Liftoff: HELP Site Activated
  4. Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
  5. Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial
  6. TENX: Tenax S-1 Filing
  7. How Should You Think About Tenax Therapeutics Inc’s (NASDAQ:TENX) Risks?
  8. Tenax Therapeutics to Present at Upcoming Investor Conferences
  9. TENX: 3Q Start to Pulmonary Hypertension Trial
  10. Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
  11. Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients
  12. Has Tenax Therapeutics Inc (NASDAQ:TENX) Improved Earnings Growth In Recent Times?
  13. TENX: Tenax 1Q:18 Results
  14. Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO
  15. Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients
  16. Why You Need To Look At This Factor Before Buying Tenax Therapeutics Inc (NASDAQ:TENX)
  17. How Do Analysts See Tenax Therapeutics Inc (NASDAQ:TENX) Performing In The Next Couple Of Years?
  18. TENX: New Indication for Levosimendan
  19. Finding Breakouts And Avoiding Fakeouts In A Market At War With Itself

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 181235530
  2. 8-K - Current report 181228824
  3. EFFECT - Notice of Effectiveness 181224781
  4. 424B4 - Prospectus [Rule 424(b)(4)] 181224142
  5. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 181219023
  6. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 181214832
  7. FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses 181196143
  8. S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933 181195910
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181184420
  10. S-1 - General form for registration of securities under the Securities Act of 1933 181163918